Ovarian function during use of Nestorone® subdermal implants

Vivian Brache, Rebeca Massai, Daniel R. Mishell, Alfred J. Moo-Young, Francisco Alvarez, Ana Maria Salvatierra, Leila Cochon, Horacio Croxatto, Ann Robbins, Anibal Faundes

Resultado de la investigación: Article

27 Citas (Scopus)

Resumen

Nestorone® progestin (NES) is a potent 19-nor-progesterone derivative which is biologically inactive when administered orally; however, it is an excellent option for implant contraception. The objective of this study was to evaluate ovarian function during use of either one 4-cm or two 3-cm NES implants for 24 months. A total of 60 volunteers were enrolled in each dose group. Vaginal ultrasound (VUS) and blood sampling for determinations of estradiol (E2), progesterone (P) and NES serum levels were carried out twice a week for 6 consecutive weeks, beginning in months 1, 6, 12, 18, and 24 of implant use. Serum levels of NES declined with time, with a more pronounced decrease during the first 18 months of implant use; thereafter, NES levels remained stable until the end of the study at 24 months. Luteal activity was very infrequent during the first year of use (<3%) but increased during the second year, occurring in 27% and 35% of the sampling periods in the 1-implant group, and 2% and 16% of the sampling periods in the 2-implant group, at months 18 and 24 of use, respectively. No luteal activity was observed with NES levels above 80 pmol/L. Serum P levels in periods of luteal activity were significantly lower than those of controls. Persistent anovulatory follicles were the most common VUS finding and this was associated with E2 levels that remained within the normal range (101-1500 pmol/L) in the majority of the sampling periods studied. Considering that a single implant offers advantage for insertion and removal, a new single NES implant is being developed with a slightly higher release rate, to reduce effectively the incidence of ovulation and provide a greater margin of safety beyond 2 years. Copyright (C) 2000 Elsevier Science Inc.

Idioma originalEnglish
Páginas (desde-hasta)199-204
Número de páginas6
PublicaciónContraception
Volumen61
N.º3
DOI
EstadoPublished - 1 mar 2000

Huella dactilar

Progestins
Corpus Luteum
Progesterone
Serum
Ovulation
ST 1435
Contraception
Volunteers
Estradiol
Reference Values
Safety
Incidence

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Citar esto

Brache, V., Massai, R., Mishell, D. R., Moo-Young, A. J., Alvarez, F., Salvatierra, A. M., ... Faundes, A. (2000). Ovarian function during use of Nestorone® subdermal implants. Contraception, 61(3), 199-204. https://doi.org/10.1016/S0010-7824(00)00092-5
Brache, Vivian ; Massai, Rebeca ; Mishell, Daniel R. ; Moo-Young, Alfred J. ; Alvarez, Francisco ; Salvatierra, Ana Maria ; Cochon, Leila ; Croxatto, Horacio ; Robbins, Ann ; Faundes, Anibal. / Ovarian function during use of Nestorone® subdermal implants. En: Contraception. 2000 ; Vol. 61, N.º 3. pp. 199-204.
@article{371aaa373be44ef8bee8422f5ee975d6,
title = "Ovarian function during use of Nestorone{\circledR} subdermal implants",
abstract = "Nestorone{\circledR} progestin (NES) is a potent 19-nor-progesterone derivative which is biologically inactive when administered orally; however, it is an excellent option for implant contraception. The objective of this study was to evaluate ovarian function during use of either one 4-cm or two 3-cm NES implants for 24 months. A total of 60 volunteers were enrolled in each dose group. Vaginal ultrasound (VUS) and blood sampling for determinations of estradiol (E2), progesterone (P) and NES serum levels were carried out twice a week for 6 consecutive weeks, beginning in months 1, 6, 12, 18, and 24 of implant use. Serum levels of NES declined with time, with a more pronounced decrease during the first 18 months of implant use; thereafter, NES levels remained stable until the end of the study at 24 months. Luteal activity was very infrequent during the first year of use (<3{\%}) but increased during the second year, occurring in 27{\%} and 35{\%} of the sampling periods in the 1-implant group, and 2{\%} and 16{\%} of the sampling periods in the 2-implant group, at months 18 and 24 of use, respectively. No luteal activity was observed with NES levels above 80 pmol/L. Serum P levels in periods of luteal activity were significantly lower than those of controls. Persistent anovulatory follicles were the most common VUS finding and this was associated with E2 levels that remained within the normal range (101-1500 pmol/L) in the majority of the sampling periods studied. Considering that a single implant offers advantage for insertion and removal, a new single NES implant is being developed with a slightly higher release rate, to reduce effectively the incidence of ovulation and provide a greater margin of safety beyond 2 years. Copyright (C) 2000 Elsevier Science Inc.",
keywords = "Luteal activity, Nestorone{\circledR} implants, Ovarian function, Persistent follicles",
author = "Vivian Brache and Rebeca Massai and Mishell, {Daniel R.} and Moo-Young, {Alfred J.} and Francisco Alvarez and Salvatierra, {Ana Maria} and Leila Cochon and Horacio Croxatto and Ann Robbins and Anibal Faundes",
year = "2000",
month = "3",
day = "1",
doi = "10.1016/S0010-7824(00)00092-5",
language = "English",
volume = "61",
pages = "199--204",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "3",

}

Brache, V, Massai, R, Mishell, DR, Moo-Young, AJ, Alvarez, F, Salvatierra, AM, Cochon, L, Croxatto, H, Robbins, A & Faundes, A 2000, 'Ovarian function during use of Nestorone® subdermal implants', Contraception, vol. 61, n.º 3, pp. 199-204. https://doi.org/10.1016/S0010-7824(00)00092-5

Ovarian function during use of Nestorone® subdermal implants. / Brache, Vivian; Massai, Rebeca; Mishell, Daniel R.; Moo-Young, Alfred J.; Alvarez, Francisco; Salvatierra, Ana Maria; Cochon, Leila; Croxatto, Horacio; Robbins, Ann; Faundes, Anibal.

En: Contraception, Vol. 61, N.º 3, 01.03.2000, p. 199-204.

Resultado de la investigación: Article

TY - JOUR

T1 - Ovarian function during use of Nestorone® subdermal implants

AU - Brache, Vivian

AU - Massai, Rebeca

AU - Mishell, Daniel R.

AU - Moo-Young, Alfred J.

AU - Alvarez, Francisco

AU - Salvatierra, Ana Maria

AU - Cochon, Leila

AU - Croxatto, Horacio

AU - Robbins, Ann

AU - Faundes, Anibal

PY - 2000/3/1

Y1 - 2000/3/1

N2 - Nestorone® progestin (NES) is a potent 19-nor-progesterone derivative which is biologically inactive when administered orally; however, it is an excellent option for implant contraception. The objective of this study was to evaluate ovarian function during use of either one 4-cm or two 3-cm NES implants for 24 months. A total of 60 volunteers were enrolled in each dose group. Vaginal ultrasound (VUS) and blood sampling for determinations of estradiol (E2), progesterone (P) and NES serum levels were carried out twice a week for 6 consecutive weeks, beginning in months 1, 6, 12, 18, and 24 of implant use. Serum levels of NES declined with time, with a more pronounced decrease during the first 18 months of implant use; thereafter, NES levels remained stable until the end of the study at 24 months. Luteal activity was very infrequent during the first year of use (<3%) but increased during the second year, occurring in 27% and 35% of the sampling periods in the 1-implant group, and 2% and 16% of the sampling periods in the 2-implant group, at months 18 and 24 of use, respectively. No luteal activity was observed with NES levels above 80 pmol/L. Serum P levels in periods of luteal activity were significantly lower than those of controls. Persistent anovulatory follicles were the most common VUS finding and this was associated with E2 levels that remained within the normal range (101-1500 pmol/L) in the majority of the sampling periods studied. Considering that a single implant offers advantage for insertion and removal, a new single NES implant is being developed with a slightly higher release rate, to reduce effectively the incidence of ovulation and provide a greater margin of safety beyond 2 years. Copyright (C) 2000 Elsevier Science Inc.

AB - Nestorone® progestin (NES) is a potent 19-nor-progesterone derivative which is biologically inactive when administered orally; however, it is an excellent option for implant contraception. The objective of this study was to evaluate ovarian function during use of either one 4-cm or two 3-cm NES implants for 24 months. A total of 60 volunteers were enrolled in each dose group. Vaginal ultrasound (VUS) and blood sampling for determinations of estradiol (E2), progesterone (P) and NES serum levels were carried out twice a week for 6 consecutive weeks, beginning in months 1, 6, 12, 18, and 24 of implant use. Serum levels of NES declined with time, with a more pronounced decrease during the first 18 months of implant use; thereafter, NES levels remained stable until the end of the study at 24 months. Luteal activity was very infrequent during the first year of use (<3%) but increased during the second year, occurring in 27% and 35% of the sampling periods in the 1-implant group, and 2% and 16% of the sampling periods in the 2-implant group, at months 18 and 24 of use, respectively. No luteal activity was observed with NES levels above 80 pmol/L. Serum P levels in periods of luteal activity were significantly lower than those of controls. Persistent anovulatory follicles were the most common VUS finding and this was associated with E2 levels that remained within the normal range (101-1500 pmol/L) in the majority of the sampling periods studied. Considering that a single implant offers advantage for insertion and removal, a new single NES implant is being developed with a slightly higher release rate, to reduce effectively the incidence of ovulation and provide a greater margin of safety beyond 2 years. Copyright (C) 2000 Elsevier Science Inc.

KW - Luteal activity

KW - Nestorone® implants

KW - Ovarian function

KW - Persistent follicles

UR - http://www.scopus.com/inward/record.url?scp=0034030098&partnerID=8YFLogxK

U2 - 10.1016/S0010-7824(00)00092-5

DO - 10.1016/S0010-7824(00)00092-5

M3 - Article

C2 - 10827334

AN - SCOPUS:0034030098

VL - 61

SP - 199

EP - 204

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 3

ER -

Brache V, Massai R, Mishell DR, Moo-Young AJ, Alvarez F, Salvatierra AM y otros. Ovarian function during use of Nestorone® subdermal implants. Contraception. 2000 mar 1;61(3):199-204. https://doi.org/10.1016/S0010-7824(00)00092-5